Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–67 of 67 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Urgency Frequency Clear all

Conditions: Overactive Bladder, Urge Urinary Incontinence, Mixed Urinary Incontinence
Interventions: Leva device; Device
Lead sponsor: The Christ Hospital; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Overactive Bladder, Urgency-Frequency
Interventions: Interstim implant for SNS; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Orange, California

Conditions: Urinary Bladder, Overactive
Interventions: warfarin, Warfarin plus Fesoterodine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions: mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo; Drug
Lead sponsor: Astellas Pharma Europe Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 36
States / cities: Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more

Conditions: Overactive Bladder, Bladder, Overactive, Urge Incontinence, Urgency Urinary, Urinary Frequency/Urgency
Interventions: Transvaginal botulinum toxin A (BTA) injection; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Overactive Bladder
Interventions: Urgent PC Neuromodulation System, Tolterodine; Device · Drug
Lead sponsor: Uroplasty, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minnetonka, Minnesota

Conditions: Interstitial Cystitis
Interventions: Acupuncture; Procedure
Lead sponsor: The Mary Elizabeth Groff Surgical Medical Research and Education Charitable Trust; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Urinary Bladder, Overactive
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 82
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more

Conditions: Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Desert Harvest Aloe Vera Capsules, Placebo Capsules; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Overactive Bladder, Urgency-frequency Syndrome, Urinary Frequency More Than Once at Night
Interventions: iStim TENS unit and Transvaginal Probe; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Urge Incontinence, Urgency-frequency Syndrome, Overactive Bladder
Interventions: Sacral neuromodulation; Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Urinary Urge Incontinence
Interventions: Sacral neuromodulation device turned off; Procedure
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
Interventions: Fesoterodine, fesoterodine plus fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Interstitial Cystitis
Interventions: Dexmedetomidine, Normal Saline; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Urinary Bladder, Overactive
Interventions: Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,792 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 106
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more

Conditions: Urinary Incontinence
Interventions: solifenacin succinate, tamsulosin, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 67 more

Conditions: Overactive Bladder
Interventions: bion; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 11
States / cities: Tucson, Arizona • Stanford, California • Englewood, Colorado + 8 more

Conditions: Urinary Frequency, Urinary Urgency, Nocturia
Interventions: Solifenacin PO; Drug
Lead sponsor: Seattle Urology Research Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer, Pelvic Pain, Incontinence
Interventions: Radical Prostatectomy, InterStim Implantation, Pelvic organ prolapse repair; Procedure
Lead sponsor: Kenneth Peters, MD; Other
Eligibility: 18 Years and older
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Royal Oak, Michigan

Search by objective public record fields.

Pelvic Floor Muscle Training With Leva System for Urge Incontinence

Comparison of Motor and Sensory Response With Interstim Stimulation

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder

Overactive Bladder Innovative Therapy Trial (OrBIT)

Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis

TEST-ON - Does iStim Reduce Urinary Urgency?

Percutaneous Nerve Evaluation Trial Time

The Effects of Sacral Neuromodulation for Urinary Urgency, Frequency, and Urge Incontinence

The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome

Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)

Urology Database for Outcomes Research